For more information, contact:

Nicole Fawcett, [email protected]




EMBARGOED for release at 4 p.m. ET Jan. 16, 2018



PD-L1 in cells within tumor microenvironment, lymph nodes matters more than tumor PD-L1, researchers report


ANN ARBOR, Michigan — While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.


“This begs the question: Why does it work in those patients? We don’t understand the mechanism at work very well,” says Weiping Zou, M.D., Ph.D., the Charles B. de Nancrede Professor of Surgery, Pathology, Immunology and Biology at the University of Michigan.


Zou and colleagues offer a clue in a new study published in the Journal of Clinical Investigation.


Researchers studied mice with colon cancer, ovarian cancer, melanoma and lung cancer to understand how expression of the protein PD-L1 affects response to its blockade. This is a key target of immunotherapy drugs. The researchers found a key link in the antigen presenting cells – macrophages and dendritic cells found in the tumor microenvironment and in the nearby lymph nodes.


“The antigen presenting cells are the real guide. PD-L1 expression in these cells is responsible for response to therapy. This reshapes our understanding of checkpoint blockade therapies and the biomarkers that may predict clinical efficacy,” Zou says.


Interestingly, his team first pinpointed the human cancer associated antigen presenting cells in 2003, in a paper published in Nature Medicine. That paper demonstrated dendritic cells express PD-L1 and blockade of PD-L1 on antigen presenting cells causes tumor regression in model systems. But this was when immunotherapy research was in its very early stages, before any of today’s therapies were introduced.


When the Food and Drug Administration approved immunotherapy drugs designed to block PD-L1 and PD-1, the indication said patients’ tumors must express PD-L1. But these therapies have worked in patients whose tumor cells did not express PD-L1. And they have failed in patients whose tumor cells do.


“Clearly, that’s not a reliable biomarker,” Zou says.


In the new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies. In both cancers, researchers found a link between the percent of antigen presenting cells expressing PD-L1 and an objective clinical response to treatment.


Currently, tumor tissue is tested broadly for PD-L1 expression. Without looking at individual cells within the tissue, it could mask the true source of PD-L1 expression. This study suggests a more complicated analysis looking for additional markers might be more informative in guiding treatment.


Additional authors: Heng Lin, Shuang Wei, Elaine M. Hurt, Michael D. Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W. Harms, Leslie A. Fecher, Pankaj Vats, Arul M. Chinnaiyan, Christopher D. Lao, Theodore S. Lawrence, Max S. Wicha, Junzo Hamanishi, Masaki Mandai, Ilona Kryczek


Funding: National Cancer Institute grants CA123088, CA099985, CA156685, CA171306, CA190176, CA193136, CA211016 and 5P30CA46592; MedImmune


Disclosure: Hurt is an employee of MedImmune. Wicha and Zou received sponsored research grants from MedImmune. Hamanishi and Mandai received support from Ono Pharmaceutical Company Japan and Bristol-Myers Squibb. Fecher received clinical trial funding from Bristol Myers Squibb.


Reference: Journal of Clinical Investigation, published online Jan. 16, 2018



University of Michigan Comprehensive Cancer Center,

Michigan Medicine Cancer AnswerLine, 800-865-1125

Michigan Health Lab,


# # #



Register for reporter access to contact details

Journal of Clinical Investigation; CA123088; CA099985; CA156685; CA171306; CA190176; CA193136; CA211016; 5P30CA46592